Who are NER1006, 2-Day Split-Dosing's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pico-Salax®, NER1006,1-Day Morning Split-Dosing, NER1006, Day Before-Only Dosing.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ner1006-2-day-split-dosing.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

NER1006, 2-Day Split-Dosing — Competitive Intelligence Brief

NER1006, 2-Day Split-Dosing (NER1006, 2-Day Split-Dosing) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bowel cleansing agent. Area: Gastroenterology.

phase 3 Bowel cleansing agent Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

NER1006, 2-Day Split-Dosing (NER1006, 2-Day Split-Dosing) — Norgine. NER1006 is a polyethylene glycol (PEG)-based bowel cleansing agent that osmotically draws fluid into the colon to evacuate intestinal contents.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
NER1006, 2-Day Split-Dosing TARGET	NER1006, 2-Day Split-Dosing	Norgine	phase 3	Bowel cleansing agent
Pico-Salax®	Pico-Salax®	The Hospital for Sick Children	marketed	Bowel cleansing agent / Laxative combination
NER1006,1-Day Morning Split-Dosing	NER1006,1-Day Morning Split-Dosing	Norgine	phase 3	Osmotic laxative / bowel cleansing agent
NER1006, Day Before-Only Dosing	NER1006, Day Before-Only Dosing	Norgine	phase 3	Osmotic laxative / Bowel cleansing agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bowel cleansing agent class)

Norgine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NER1006, 2-Day Split-Dosing — Competitive Intelligence Brief. https://druglandscape.com/ci/ner1006-2-day-split-dosing. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab